PedAM
Pediatric Disease Annotations & Medicines
| Disease | hypercalcemia |
| Phenotype | C0026764|myeloma |
| Sentences | 11 |
| PubMedID- 26500541 | We report a case of multiple myeloma complicated by severe hypercalcemia associated with volume contraction, hypokalemia and a metabolic alkalosis likely associated with activation of the calcium-sensing receptor, perhaps the first clinical description of this laboratory finding. |
| PubMedID- 22073517 | Multiple myeloma with hypercalcemia and chloride resistant metabolic alkalosis. |
| PubMedID- 24334568 | It is the most common primary bone malignancy, and the extensive osteoclastic bone resorption common in multiple myeloma is associated with hypercalcemia in as many as one-third of patients. |
| PubMedID- 23571233 | These drugs are used in the treatment of osteoporosis, paget's disease, hypercalcaemia associated with malignancy, multiple myeloma, etc. |
| PubMedID- 21915243 | Interestingly, aminobisphosphonates (abs) which are synthetic compounds commonly used to treat bone disease and hypercalcemia in patients with multiple myeloma, breast or prostate cancer, have been identified also as antigens for γδ t cells, indicating these molecules as immunomodulating factors [21]–[26]. |
| PubMedID- 22082730 | Introduction: osteonecrosis of the jaw (onj) is an emerging condition in patients undergoing long-term administration of bisphosphonates (bp) for the treatment of osteoporosis and hypercalcaemia associated with malignancy, multiple myeloma, and metastatic breast and prostate cancers. |
| PubMedID- 23700375 | After the diagnosis of multiple myeloma with hypercalcemia, specific treatment was instigated, according to the following protocol (figure 2): intravenous normal saline (na, 154 mmol/l; cl, 154 mmol/l; 500 ml × 2/day; daily), dexamethasone (8 mg per day × 2 consecutive days), nahco3 (80 mmol/l per day; daily), bortezomib (1.3 mg/m2 per dose, weekly), elcatonin (40 units per day for 5 consecutive days), and zoledronic acid hydrate (4 mg per dose, monthly). |
| PubMedID- 24743202 | Bisphosphonates(bps)have been widely used for the treatment of hypercalcemia associated with cancer, multiple myeloma bone diseases, and bone metastasis of solid cancers. |
| PubMedID- 22968855 | In addition, hypercalcemia associated with osteolysis by myeloma cells, deposition of amyloid in glomeruli, hyperviscosity syndrome, hyperphosphatemia, renal infiltration of myeloma cells are also the causes of renal dysfunction. |
| PubMedID- 25128013 | Denosumab for the management of hypercalcemia of malignancy in patients with multiple myeloma and renal dysfunction. |
| PubMedID- 22185991 | A case of myeloma with hypercalcemia caused by high serum concentrations of both parathyroid hormone-related peptide (pthrp) and macrophage inflammatory protein-1alpha (mip-1alpha). |
Page: 1